69 related articles for article (PubMed ID: 37099447)
1. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
Giguère P; Deschenes MJ; Loon MV; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
Clin J Am Soc Nephrol; 2023 Apr; 18(7):913-9. PubMed ID: 37099447
[TBL] [Abstract][Full Text] [Related]
2. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
[TBL] [Abstract][Full Text] [Related]
3. Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19.
Zhang W; Zhang X; Han J; Zhang W; Xu J; Zhang X; Bian H; Meng C; Shang D; Zhou Y; Wang D; Feng B
Front Pharmacol; 2024; 15():1389187. PubMed ID: 38601471
[TBL] [Abstract][Full Text] [Related]
4. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
5. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.
Xu X; Zhang H; Liu L; Fu Q; Wu C; Lin X; Tang K; Wang C; Chen P
Eur J Clin Pharmacol; 2024 May; ():. PubMed ID: 38691139
[TBL] [Abstract][Full Text] [Related]
7. Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report.
Dowd-Green C; Brown D; Wilson A; Streiff M
J Pharm Pract; 2024 May; ():8971900241257296. PubMed ID: 38803049
[No Abstract] [Full Text] [Related]
8. Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.
Hiremath S; Blake PG; Yeung A; McGuinty M; Thomas D; Ip J; Brown PA; Pandes M; Burke A; Sohail QZ; To K; Blackwell L; Oliver M; Jain AK; Chagla Z; Cooper R
Clin J Am Soc Nephrol; 2023 Apr; 18(4):485-490. PubMed ID: 36723285
[TBL] [Abstract][Full Text] [Related]
9. Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk.
Dai J; Fuquay T; Huseman S; Patel D; Datta P; Krutsch K
Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38923506
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
Yang H; Yu X; Hou W; Liu X; Chen J; Zhang Y; Wang Y; Zhu Y; Qian Q; Ma K; An Z
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0138423. PubMed ID: 38289075
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID-19.
Ng TM; Wang Z; Chan ECY
Br J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38616514
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation" [Clin Microbiol Infect 28 (12) (2022 Dec) 1657-1658].
Antonelli G; Focosi D; Turriziani O; Tuccori M; Brandi R; Fillo S; Ajassa C; Lista F; Mastroianni CM
Clin Microbiol Infect; 2024 Mar; 30(3):408. PubMed ID: 38103639
[No Abstract] [Full Text] [Related]
13. Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.
Spetko N; Wang BX; Herzig SJ; Anderson TS
J Gen Intern Med; 2024 Apr; ():. PubMed ID: 38600400
[No Abstract] [Full Text] [Related]
14. Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection.
Qu Y; Su C; Xiang Z; Wang Y; Han J; Pan J; Shen Z
Eur J Pharm Sci; 2023 Oct; 189():106535. PubMed ID: 37487949
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
Qin F; Wang H; Li M; Zhuo S; Liu W
Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
[TBL] [Abstract][Full Text] [Related]
16. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
Liu TH; Wu JY; Huang PY; Tsai YW; Lai CC
J Med Virol; 2023 Jul; 95(7):e28951. PubMed ID: 37436873
[TBL] [Abstract][Full Text] [Related]
17. Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.
Wang Y; Zhao D; Xiao W; Shi J; Chen W; Jia Q; Zhou Y; Wang R; Chen X; Feng L
J Med Virol; 2023 Aug; 95(8):e29014. PubMed ID: 37522243
[No Abstract] [Full Text] [Related]
18. Risk of acute liver injury following the nirmatrelvir/ritonavir use.
Wong CKH; Mak LY; Au ICH; Cheng WY; So CH; Lau KTK; Lau EHY; Cowling BJ; Leung GM; Yuen MF
Liver Int; 2023 Dec; 43(12):2657-2667. PubMed ID: 37448114
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
